The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montreal, Canada

被引:20
|
作者
Godin, Arnaud [1 ]
Kronfli, Nadine [2 ,3 ]
Cox, Joseph [1 ,2 ,3 ]
Alary, Michel [4 ,5 ,6 ]
Maheu-Giroux, Mathieu [1 ]
机构
[1] McGill Univ, Sch Populat & Global Hlth, Dept Epidemiol Biostat & Occupat Hlth, Fac Med, 1020 Ave Pins Ouest,Rm 43, Montreal, PQ H3A 1A2, Canada
[2] McGill Univ, Div Infect Dis, Dept Med, Hlth Ctr, Montreal, PQ, Canada
[3] McGill Univ, Chron Viral Illness Serv, Hlth Ctr, Montreal, PQ, Canada
[4] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada
[5] Univ Laval, Axe Sante Populat & Prat Optimales Sante, Ctr Rech CHU Quebec, Quebec City, PQ, Canada
[6] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada
基金
加拿大健康研究院;
关键词
People in prison; People who inject drugs; Linkage to care; HCV; Micro-elimination; SPONTANEOUS CLEARANCE; RELEASE; CARE; IMPACT; METAANALYSIS; INFECTION; COMMUNITY; HIV; INCARCERATION; FACILITATORS;
D O I
10.1016/j.drugpo.2020.102738
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Canada, hepatitis C virus (HCV) transmission primarily occurs among people who inject drugs (PWID) and people with experience in the prison system bare a disproportionate disease burden. These overlap-ping groups of individuals have been identified as priority populations for HCV micro-elimination in Canada, which is currently not on track to achieve its elimination targets. Considering the missed opportunities to inter-vene in provincial prisons, this study aims to estimate the population-level impact of prison-based interventions and post-release risk reduction strategies on HCV transmission among PWID in Montreal, a Canadian city with high HCV burden. Methods: A dynamic HCV transmission model among PWID was developed and calibrated to community and prison bio-behavioural surveys in Montreal. Then, the relative impact of prison-based testing and treatment or post-release linkage to care (both 90% testing and 75% treatment coverage), alone or in combination with strategies that reduce the heightened post-release transmission risk by 50%, was estimated from 2018 to 2030, and compared to counterfactual scenarios. Results: Prison-based test-and-treat strategies could lead to the greatest declines in incidence (48%; 95%CrI: 38-57%) over 2018-2030 and prevent the most new first chronic infections (22%; 95%CrI: 16 - 28%) among people never exposed to HCV. Prison testing and post-release linkage to care lead to a slightly lower decrease in incidence and prevented fraction of new chronic infections. Combining test-and-treat with risk reduction measures could further its epidemiological impact, preventing 35% (95%CrI: 29 - 40%) of new first chronic infections. When implemented concomitantly with community-based treatment scale-up, prison-based interventions had synergistic effects, averting a higher fraction of new first chronic infections. Conclusion: Offering HCV testing and treatment in provincial prisons, where incarcerations are frequent and sentences short, could change the course of the HCV epidemic in Montreal. Prison-based interventions with potential integration of post-release risk reduction measures should be considered as an integral part of HCV micro-elimination strategies in this setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] EVALUATING INTERVENTIONS TO ELIMINATE HEPATITIS C AMONG PEOPLE WHO INJECT DRUGS IN THE UNITED STATES
    Blake, Andrew
    Smith, James E.
    MEDICAL DECISION MAKING, 2021, 41 (04) : E255 - E257
  • [42] Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago
    Echevarria, Desarae
    Gutfraind, Alexander
    Boodram, Basmattee
    Layden, Jennifer
    Ozik, Jonathan
    Page, Kimberly
    Cotler, Scott J.
    Major, Marian
    Dahari, Harel
    VACCINE, 2019, 37 (19) : 2608 - 2616
  • [43] Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
    Rivero-Juarez, Antonio
    Tellez, Francisco
    Mayorga, Maria Isabel
    Merino, Dolores
    Espinosa, Nuria
    Macias, Juan
    Palacios, Rosario
    Paniagua, Maria
    Collado, Antonio
    Mohamed, Omar
    Perez-Stachowski, Javier
    Hernandez-Quero, Jose
    Fernandez-Fuertes, Elisa
    Rivero, Antonio
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (05) : 800 - 801
  • [44] Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
    Messina, Vincenzo
    Pisaturo, Mariantonietta
    Alessio, Loredana
    Russo, Antonio
    Tripaldelli, Elena
    Petruzziello, Arnolfo
    Annecchiarico, Angela
    Romano, Maria Rosaria
    Maggi, Paolo
    Coppola, Nicola
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (05) : 562 - 565
  • [45] Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion
    Chu, Carissa E.
    Wu, Feng
    He, Xi
    Zhou, Kali
    Cheng, Yu
    Cai, Weiping
    Geng, Elvin
    Volberding, Paul
    Tucker, Joseph D.
    OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (02):
  • [46] The modeled impact of improved Hepatitis C Virus (HCV) treatment strategies on HCV prevalence among people who inject drugs (PWIDs) in Belgium
    Mathei, Catharina
    Bourgeois, Stefan
    Brixko, Christian
    Blach, Sarah
    Mulkay, Jean-Pierre
    Razavi, Homie
    Serste, Thomas
    Robaeys, Geert
    HEPATOLOGY, 2015, 62 : 1106A - 1107A
  • [47] A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs
    Hope, Vivian D.
    Harris, Ross J.
    Vickerman, Peter
    Platt, Lucy
    Shute, Justin
    Cullen, Katelyn J.
    Ijaz, Samreen
    Mandal, Sema
    Ncube, Fortune
    Desai, Monica
    Parry, John V.
    EUROSURVEILLANCE, 2018, 23 (47) : 33 - 44
  • [48] Hepatitis C virus infection in people who inject drugs in Africa
    Shah, Rajiv
    Boucheron, Pauline
    Mandaliya, Kishor
    Kattamaiyo, Alex
    Chevaliez, Stephane
    Shimakawa, Yusuke
    Songok, Elijah
    Lemoine, Maud
    LANCET INFECTIOUS DISEASES, 2020, 20 (03): : 282 - 283
  • [49] Hepatitis C virus treatment as prevention in people who inject drugs
    White, Peter J.
    Abubakar, Ibrahim
    LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 379 - 379
  • [50] A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination
    Lazarus, Jeffrey
    Picchio, Camila
    Byrne, Christopher
    Crespo, Javier
    Colombo, Massimo
    Cooke, Graham
    Dore, Gregory
    Grebely, Jason
    Ward, John
    White, Trenton
    Dillon, John
    JOURNAL OF HEPATOLOGY, 2021, 75 : S661 - S662